SCIENTIFIC REPORTS

OPEN

Received: 08 December 2015 Accepted: 11 May 2016 Published: 27 May 2016

Robotic-assisted surgery versus open surgery in the treatment of rectal cancer: the current evidence

Guixiang Liao^{1,*}, Yan-Bing Li^{2,*}, Zhihong Zhao^{3,*}, Xianming Li¹, Haijun Deng⁴ & Gang Li⁵

The aim of this meta-analysis was to comprehensively compare the safety and efficacy of roboticassisted rectal cancer surgery (RRCS) and open rectal cancer surgery (ORCS). Electronic database (PubMed, EMBASE, Web of Knowledge, and the Cochrane Library) searches were conducted for all relevant studies that compared the short-term and long-term outcomes between RRCS and ORCS. Odds ratios (ORs), mean differences, and hazard ratios were calculated. Seven studies involving 1074 patients with rectal cancer were identified for this meta-analysis. Compared with ORCS, RRCS is associated with a lower estimated blood loss (mean difference [MD]: -139.98, 95% confidence interval [CI]: -159.11 to -120.86; P < 0.00001), shorter hospital stay length (MD: -2.10, 95% CI: -3.47 to -0.73; P = 0.003), lower intraoperative transfusion requirements (OR: 0.52, 95% CI: 0.28 to 0.99, P = 0.05), shorter time to flatus passage (MD: -0.97, 95% CI = -1.06 to -0.88, P < 0.00001), and shorter time to resume a normal diet (MD: -1.71.95% CI = -3.31 to -0.12, P = 0.04). There were no significant differences in surgery-related complications, oncologic clearance, disease-free survival, and overall survival between the two groups. However, RRCS was associated with a longer operative time. RRCS is safe and effective.

Minimally invasive surgery is widely applied in many surgical fields. Robotic-assisted surgery is an advanced minimally invasive technique, has been applied in many branches of surgery (gynecologic¹, urologic², and gastro-intestinal³), seems to achieve promising results, and has gained worldwide attention.

Robotic-assisted colorectal surgery was first reported in 2002⁴. Since then, a variety of reports regarding robotic-assisted rectal surgery have been published⁵⁻⁹. Robotic surgery is considered a good choice in the treatment of rectal cancer because this technique can overcome difficulties associated with the anatomy of the pelvis and has certain advantages¹⁰⁻¹², including 3D imaging, dexterity and ambidextrous capability, lack of tremors, motion scaling, and a short learning curve^{13,14}. Some reports have already indicated that robotic colorectal surgery has some benefits over conventional laparoscopic surgery based on observational comparative studies or randomized controlled trials^{15,16}. However, the feasibility and safety of robotic-assisted rectal surgery compared with open rectal surgery in treating rectal cancer are not well elucidated. We conducted this meta-analysis to assess the safety and efficacy of robotic surgery versus open surgery in treating rectal cancer.

Methods

Search strategy. This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement¹⁷. A comprehensive literature search was carried out by reviewers using the following electronic databases: PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. The search was conducted in July 2014, and the language was restricted to English. The following search terms were used: robot or robotic or robot-assisted or da vinci or davinci, open, rectal or rectum or colorectal, and cancer or tumor or carcinoma.

¹Department of Radiation Oncology, Shenzhen People's Hospital, Second Clinical Medicine College of Jinan University, China. ²Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Hubei University of Medicine, Hubei, China. ³Department of Nephrology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China. ⁴Department of General Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China. ⁵Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. ^{*}These authors contributed equally to this work. Correspondence and requests for materials should be addressed to X.L. (email: chenlhnfy@163.com) or G.L. (email: andrewlee0923@163.com)




Figure 1. Flowchart of the literature search.

The study inclusion criteria were as follows: (1) the study was a comparative study that compared the safety and efficiency between robotic rectal cancer surgery (RRCS) and open rectal cancer surgery (ORCS); (2) the study included quantitative outcome data (e.g., operative time, length of hospital stay, complications, pathological parameters, and survival outcomes); (3) if the same institution and/or authors reported several studies, only the study with the greatest patient population or the highest quality study was included in the analysis; and (4) the study was published in English. We excluded editorials, comments, meeting abstracts, review articles, and non-relevant topic studies.

Data extraction. The primary relevant data from all the included studies were extracted by two reviewers (GXL, ZZ). The extracted data included the following: the basic characteristics of the study, including first author, year, and country of publication; the publication journal name; the basic patient characteristics, including age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) score, case number, and tumor stage; short-term outcomes, including intraoperative data, postoperative data, and oncologic clearance; and long-term outcomes, including disease-free survival and overall survival. All available data were extracted using standard data extraction by one reviewer and were checked by another reviewer.

Quality assessment. Two reviewers (GL, YL) independently evaluated the quality of each included study using the modified Newcastle-Ottawa scale (available at http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp), which is widely used for cohort study assessment. The quality assessment consisted of three major categories: patient selection, comparability of the RRCS and ORCS groups, and outcome assessment¹⁸. The details of this quality assessment are provided in Table S1. Any disagreement was resolved via discussion among the author group.

Statistical analysis. This meta-analysis was performed using the Review Manager software (version 5.2, provided by the Cochrane Collaboration) and Stata software (version 11.0). Dichotomous variables were analyzed using odds ratios (ORs) with 95% confidence intervals (95% CIs). Survival outcomes were estimated using hazards ratios (HRs) and standard errors. Continuous variables were analyzed using mean differences (MDs) and 95% CIs. A fixed-effects model or a random-effects model was applied according to heterogeneity, which was evaluated by the I² measure of inconsistency. Heterogeneity was present when the I² statistic was greater than 50%, and a random-effects model was adopted. However, when the I² statistic value was less than 50%, a fixed-effects model was used. Publication bias was evaluated by a funnel plot of postoperative complications and Egg's and Begg's tests. Sensitivity analysis was performed by excluding the low-quality studies. A *P* value less than 0.05 was considered to be significant.

Results

Literature search. The PubMed, EMBASE, Web of Science, and Cochrane Library search identified a total of 277 studies. After excluding duplicates using Endnote software, 180 abstracts were carefully reviewed by two independent reviewers using a standard study selection form. After this process, the reviewers identified 10 studies for a comprehensive review. Three studies were excluded according to the inclusion criteria^{19–21}, leaving 7 studies that were included in our analysis^{22–28}. The study selection process is shown in Fig. 1. A total of 1074 patients

Author	Year	Country	Journal name	Study type	Group	N	Sex M/F	BMI	Age	ASA (1/2/3/4)	T Stage(0/1/2/3/4)	Opera- tion type
Barnajian M ²²	2014	USA	Colorec- tal Dis	Retrospective case-matched	RRCS ORCS	20 20	12/8 12/8	22 (3.25) 22 (3.25)	62 (9.5) 61 (10)	0/4/16/0 0/4/16/0	NA	TME
Bertani E ²³	2011	Italy	Int J Colorec- tal Dis	prospective co- hort comparative	RRCS ORCS	52 34	31/21 20/14	24.8 (3.62) 25.6 (3.85)	59.6 (11.6) 63.2 (10.5)	49/3 ^a 28/6 ^a	NA	TME
Desouza AL ²⁴	2011	USA	Dis Colon Rectum	Retrospective co- hort comparative	RRCS ORCS	36 46	22/14 25/21	27.4 (5.71) 28.7 (6.58)	63.5 (11.5) 63.7 (12.1)	27/9 ^a 31/15 ^a	1/8/10/17/0 0/6/12/28/0	TME
Ghezzi TL ²⁵	2014	Brazil	Oncol	Prospective co- hort comparative	RRCS ORCS	65 109	41/24 61/48	24.7 (3.6) 25.4 (3.6)	61.0 (11.8) 61.1 (11.0)	12/49/4/0 16/63/29/1	10/5/17/27/6 15/10/38/42/4	TME
Kang J ²⁶	2013	Korea	Ann Surg Case- matched	Prospective	RRCS ORCS	165 165	104/61 110/55	23.1 (2.8) 23.0 (3.0)	61.2 (11.4) 59.2 (11.0)	109/56/0/0 125/40/0/0	31/42/87/5 ^b 31/48/78/8	TME
Kim JC ²⁷	2014	Korea	Surg Endosc	Retrospective co- hort comparative	RRCS ORCS	108 114	64/44 78/36	23.7 (2.7) 23.2 (3)	$57\pm11\\61\pm9$	31/74/3/0 29/84/1/0	NA	AIR
Park JS ²⁸	2011	Korea	Surg Endosc	Retrospective co- hort comparative	RRCS ORCS	52 88	28/24 57/31	23.7 (2.4) 23.3 (3)	57.3 (12.3) 62.3 (10.4)	21/26/5/0 43/37/8/0	0/3/18/31/0 0/7/30/48/3	TME

Table 1. Basic characteristics of the included studies. $^{a}(1+2)/(3+4)$; TME: total mesorectal excision; AIR:abdominal intersphincteric resection. $^{b}0 + 1/2/3/4$.

.....

with 498 (9.00%) cases of RRCS and 576 cases of ORCS were analyzed. Information on the studies and the participants is shown in Table 1. The quality assessment score of each included study is also provided in Table 1, and the details of each included study assessment are provided in Table S2.

Meta-analysis. *Intraoperative data.* Operative times. The operative time was reported in all of the included studies^{22–28}. The pooled data revealed that the operative time was significantly longer in the RRCS group compared with the ORCS group (MD = 55.76; 95% CI = 29.31–82.22; P < 0.0001), and the heterogeneity was high (P < 0.00001, $I^2 = 91\%$) (Fig. 2A).

Estimated blood losses. Five of the studies assessed intraoperative estimated blood loss (EBL)^{22–26}. The EBL was significantly lower, by 139.98 ml, in the RRCS group compared with the ORCS group (MD: -139.98, 95% CI: -159.11 to -120.86; P < 0.00001). There was no significant heterogeneity (I²=33%, P=0.20) (Fig. 2B).

Intraoperative transfusion. Intraoperative transfusion was mentioned in three studies^{26–28}. Our results revealed that intraoperative transfusion requirements were reduced in the RRCS group compared with the ORCS group (OR: 0.52, 95% CI: 0.28–0.99, P = 0.05), and the analysis revealed significant heterogeneity (P = 0.28, $I^2 = 21\%$) (Fig. 2C).

Postoperative data. Overall postoperative complications. All of the included studies mentioned this index²²⁻²⁸, and the overall postoperative complication rates were similar between studies. The pooled data showed that the total postoperative complications of the two groups were not significantly different (OR = 1.00, 95% CI: 0.75 -1.32, P = 0.97), and there was no evidence of heterogeneity (P = 0.56, $I^2 = 0$) (Fig. 3A).

Postoperative mortality. Two studies mentioned postoperative mortality^{24,28}. The pooled data analysis indicated that the mortality rate was not different between the two techniques (OR: 0.87, 95% CI: 0.11–6.86, P=0.90), and there was no heterogeneity (P=0.70, $I^2=0$) (Fig. 3B).

Anastomotic leakage. Seven studies reported anastomotic leakage events^{22–28}. The anastomotic leakage rate was 6.63% in the RRCS group and 4.51% in the ORCS group. The pooled data analysis revealed that this rate was not significantly different between the two groups (OR = 1.54, 95% CI = 0.90–2.66, P = 0.12), and there was no evidence of heterogeneity (P = 0.93, I² = 0) (Fig. 3C).

Wound infection. Four studies reported the incidence of wound infection^{23,24,26,28}. The combined data revealed that this parameter was not different between the two groups (OR = 0.37, 95% CI: 0.05–2.50, P = 0.31) (Fig. 3D).

Pelvic abscess. Four studies described the number of pelvic abscess events^{23,24,26,28}. The pooled analysis indicated that there was no significant difference in this variable between the two approaches (OR = 1.11, 95% CI: 0.47–2.61, P = 0.80), and there was no heterogeneity (P = 0.55, I^2 = 0) (Fig. 3E).

Ileus. Ileus events were reported in four studies^{22,26,27,28}. The incidence of ileus in the RRCS group was 3.81%, compared with 3.26% in the ORCS group. The results showed no significant difference between the two groups (OR = 1.11, 95% CI: 0.47–2.61, P = 0.80), and there was no heterogeneity among the studies (Fig. 3F).

A operative time

		RRCS			ORCS			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Barnajian M 2014	240	90	20	240	97.5	20	9.4%	0.00 [-58.15, 58.15]	
Bertani E 2011	260	96.94	52	164	63.78	34	13.5%	96.00 [62.03, 129.97]	
Desouza AL 2011	337.9	81.8	36	273.8	100.8	46	12.5%	64.10 [24.57, 103.63]	
Ghezzi TL 2014	299	58	65	207.5	56.5	109	16.1%	91.50 [73.86, 109.14]	
Kang J 2013	309.7	115.2	165	252.6	88.1	165	15.5%	57.10 [34.97, 79.23]	
Kim J 2014	191	39	108	124	29	114	17.0%	67.00 [57.92, 76.08]	-
Park JS 2011	232.6	52.4	52	233.8	59.2	88	16.0%	-1.20 [-20.06, 17.66]	
Total (95% CI) Heterogeneity: Tau ² =	1040.25	· Chi2 -	498	df - 6 (P < 0.0	576	100.0%	55.76 [29.31, 82.22]	_
Test for overall effect:				ui – 0 (F = 0.00	JUUT), I	- 9176		-100 -50 0 50 100 Favours RRCS Favours ORCS

B estimated blood loss

		RRCS			ORCS			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Barnajian M 2014	125	150	20	250	187.5	20	3.3%	-125.00 [-230.23, -19.77]	
Bertani E 2011	100	242.35	52	120	497.44	34	1.1%	-20.00 [-199.71, 159.71]	~
Desouza AL 2011	187.5	98.1	36	273.8	165.4	46	11.0%	-86.30 [-143.85, -28.75]	
Ghezzi TL 2014	0	44.64	65	150	102.05	109	75.4%	-150.00 [-172.02, -127.98]	_
Kang J 2013	133	192.3	165	275.48	368.8	165	9.1%	-142.48 [-205.94, -79.02]	
Total (95% CI)			338			374	100.0%	-139.98 [-159.11, -120.86]	♦
Heterogeneity: Chi ² = Test for overall effect		•							-200 -100 0 100 200
			,						Favours RRCS Favours ORCS
C intraoperativ	e trans	stusior	1						

	RRC	s	ORC	s		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl	
Kang J 2013	9	165	21	165	71.8%	0.40 [0.18, 0.89]			
Kim J 2014	5	108	8	114	26.9%	0.64 [0.20, 2.03]			
Park JS 2011	1	52	0	88	1.3%	5.16 [0.21, 128.90]			_
Total (95% CI)		325		367	100.0%	0.52 [0.28, 0.99]		•	
Total events	15		29						
Heterogeneity: Chi ² =	2.52, df =	2 (P = 0).28); I² =	21%			0.01	0.1 1 10 10	+- 00
Test for overall effect:	Z = 2.00 (P = 0.0	5)				0.01	0.1 1 10 10 Favours RRCS Favours ORCS	00

Figure 2. Meta-analysis of intraoperative data on robotic-assisted rectal cancer surgery versus open rectal cancer surgery. (A) operative time, (B) estimated blood loss, (C) intraoperative transfusion requirements.

Bleeding. Three studies described bleeding^{22,26,28}. The pooled data analysis revealed no significant difference in bleeding between the two techniques (OR: 2.05, 95% CI: 0.52–8.13, P = 0.31), and no significant heterogeneity existed among the studies (Fig. 3G).

Urinary retention. Three studies reported urinary retention^{22,24,28}. The combined data indicated that urinary retention in the two groups was not significantly different (OR: 0.52, 95% CI: 0.10 to 2.77, P = 0.44), and there was no significant heterogeneity (Fig. 3H).

Length of hospital stay. All of the studies^{22–28} described length of hospital stay (LOS). The pooled data of the included studies showed that the LOS was significantly reduced in the RRCS group compared with the ORCS group (MD: -2.10, 95% CI: -3.47 to -0.73; P = 0.003). However, the heterogeneity was high (P < 0.00001, $I^2 = 92\%$) (Fig. 4A).

Pain score. Pain scores were reported in two studies^{27,28}. The pooled data of the two studies showed no difference between the two approaches with respect to pain scores (MD: -0.61, 95% CI: -1.78 to 0.57, P = 0.31), and there was high heterogeneity (P = 0.003, $I^2 = 92\%$) (Fig. 4B).

Flatus passage. Six studies reported the time to flatus passage^{22,23,25–28}. The combined data indicated that RRCS significantly reduced the time to first flatus passage by 0.97 days compared with the ORCS group (MD: -0.97, 95% CI = -1.06 to -0.88, P < 0.00001), without significant heterogeneity among the studies (P = 0.79, $I^2 = 0$) (Fig. 4C).

Time to diet resumption. The time to normal diet resumption included the time to normal diet resumption and the time to resumption of a soft diet^{22,23,25,26,28}. The combined analysis showed that the RRCS group had a significantly shorter time to diet resumption (MD: -1.71.95% CI = -3.31 to -0.12, P = 0.04). However, there was high heterogeneity among the studies (P < 0.00001, $I^2 = 97\%$) (Fig. 4D).

	complication						
	RRC		ORC			Odds Ratio	Odds Ratio
Study or Subgroup	Events 8	Total 20	Events 3	Total 20	Weight		M-H. Fixed. 95% Cl
Barnajian M 2014 Bertani E 2011	14	52	11	34	1.8% 9.8%	3.78 [0.83, 17.25] 0.77 [0.30, 1.98]	
Desouza AL 2011	11	36	15	46	9.3%	0.91 [0.36, 2.33]	-+-
Ghezzi TL 2014	27	65	45	109	19.9%	1.01 [0.54, 1.89]	
Kang J 2013 Kim J 2014	34 24	165 108	41 20	165 114	32.9% 15.3%	0.78 [0.47, 1.32]	
Park JS 2014	10	52	18	88	10.9%	0.93 [0.39, 2.19]	
							1
otal (95% CI) otal events	128	498	153	576	100.0%	1.00 [0.75, 1.32]	T
leterogeneity: Chi ² =		6 (P =)		0%			
est for overall effect:							0.02 0.1 1 10 50 Favours RRCS Favours ORCS
postoperative mortality	У						
	RRC	S	ORC	5		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% CI	M-H. Fixed, 95% Cl
Desouza AL 2011	1	36	1	46	43.5%	1.29 [0.08, 21.29]	
Park JS 2011	0	52	1	88	56.5%	0.56 [0.02, 13.89]	-
Total (95% CI)		88		134	100.0%	0.87 [0.11, 6.86]	
lotal events	1		2				
Heterogeneity: Chi ² = Test for overall effect:				0%			0.01 0.1 1 10 100
		0.9	(0)				Favours RRCS Favours ORCS
anastomotic leakage							
	RRC	e	ORC	2		Odds Ratio	Odds Ratio
Study or Subgroup					Weight		
Barnajian M 2014	2	20	1	20	4.3%	2.11 [0.18, 25.35]	
Bertani E 2011	6	52	3	34	15.2%	1.35 [0.31, 5.80]	
Desouza AL 2011 Ghezzi TL 2014	2	36 65	1	46 109	3.9% 20.0%	2.65 [0.23, 30.41] 1.13 [0.31, 4.15]	
Ghezzi TL 2014 Kang J 2013	4	65 165	6 5	109	20.0%	1.13 [0.31, 4.15] 2.51 [0.86, 7.29]	
Kim J 2014	2	108	2	114	9.1%	1.06 [0.15, 7.64]	
Park JS 2011	5	52	8	88	25.5%	1.06 [0.33, 3.44]	-
fotal (95% CI)		498		576	100.0%	1.54 [0.90, 2.66]	•
Total events	33		26	010			•
leterogeneity: Chi ² =	1.83, df = 6		0.93); l ² =	0%			0.01 0.1 1 10 100
Test for overall effect:							Favours RRCS Favours ORCS
wound infection							
	RRCS		ORCS			Odds Ratio	Odds Ratio
Study or Subgroup Bertani E 2011	Events 1	Total 52	Events 1 5	Total 34	Weight 26.4%	M-H. Random. 95% C 0.11 [0.01, 1.02]	
Desouza AL 2011	4	36	1	46	26.0%	5.63 [0.60, 52.72]	
Kang J 2013	1	165	8	165	27.2%	0.12 [0.01, 0.97]	
Park JS 2011	0	52	3	88	20.4%	0.23 [0.01, 4.59]	
Fotal (95% CI)		305		333	100.0%	0.37 [0.05, 2.50]	
Total events	6		17				
Heterogeneity: Tau ² = Test for overall effect: .				= 0.05)	; l² = 63%		0.01 0.1 1 10 100
	RRC: Events	Total		Total	Weight	Odds Ratio M-H. Fixed. 95% Cl	Odds Ratio M-H. Fixed. 95% Cl
Barnajian M 2014	Events 2	Total 20	Events 0	Total 20	4.4%	M-H. Fixed, 95% Cl 5.54 [0.25, 123.08]	
Barnajian M 2014 Bertani E 2011	Events 2 1	<u>Total</u> 20 52	Events 0 2	<u>Total</u> 20 34	4.4% 23.7%	M-H. Fixed, 95% CI 5.54 [0.25, 123.08] 0.31 [0.03, 3.60]	
Barnajian M 2014 Bertani E 2011 Kang J 2013	Events 2	Total 20	Events 0	Total 20	4.4%	M-H. Fixed, 95% Cl 5.54 [0.25, 123.08]	
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011	Events 2 1 7	Total 20 52 165 52	Events 0 2 6	Total 20 34 165 88	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI)	Events 2 1 7 1	Total 20 52 165	Events 0 2 6 2	Total 20 34 165 88	4.4% 23.7% 57.4%	M-H. Fixed. 95% CI 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57]	
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total events	Events 2 1 7 1	Total 20 52 165 52 289	Events 0 2 6 2	Total 20 34 165 88 307	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	M-H. Fixed. 95% Cl
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: Chi ^p =	Events 2 1 7 1 2.12, df = 3	Total 20 52 165 52 289 3 (P = 1	Events 0 2 6 2 10 0.55); i ² =	Total 20 34 165 88 307	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Fotal (95% CI) Fotal events teterogeneity: ChP = Fest for overall effect:	Events 2 1 7 1 2.12, df = 3	Total 20 52 165 52 289 3 (P = 1	Events 0 2 6 2 10 0.55); i ² =	Total 20 34 165 88 307	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	M-H. Fixed. 95% Cl
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP = Test for overall effect:	Events 2 1 7 1 2.12, df = 3	Total 20 52 165 52 289 3 (P = 1	Events 0 2 6 2 10 0.55); i ² =	Total 20 34 165 88 307	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	M-H. Fixed. 95% Cl
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP = Test for overall effect:	Events 2 1 7 1 2.12, df = 3	Total 20 52 165 52 289 3 (P = I P = 0.8	Events 0 2 6 2 10 0.55); i ² =	Total 20 34 165 88 307 0%	4.4% 23.7% 57.4% 14.5%	<u>M-H, Fixed, 95% Ci</u> 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53]	M-H. Fixed. 95% Cl
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP = Test for overall effect: F ileus Study or Subgroup	Events 2 1 7 1 2.12, df = 5 Z = 0.25 (f RRC: Events	Total 20 52 165 52 289 3 (P = 1 P = 0.8 S Total	Events 0 2 6 2 10 0.555): i ² = 0) ORC: Events	Total 20 34 165 88 307 0% 5 <u>Total</u>	4.4% 23.7% 57.4% 14.5% 100.0% Weight	MH. Fixed. 95% CI 5.54 [0.25, 123.08] 0.31 [0.03, 3.60] 1.17 [0.39, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] Odds Ratio MH. Fixed. 95% CI	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Mang J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP = Test for overall effect: F ileus Study or Subgroup Barnajian M 2014	Events 2 1 7 1 1 2.12, df = 5 Z = 0.25 (f RRC: <u>Events</u> 2	<u>Total</u> 20 52 165 52 289 3 (P = 1 P = 0.8 S <u>Total</u> 20	Events 0 2 6 2 10 0.55): I ² = 10) ORC: Events 1	Total 20 34 165 88 307 0% 5 <u>Total</u> 20	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7%	M-H. Fixed. 95% CI 5.54 (0.25, 123.08) 0.31 (0.03, 3.60) 1.17 (0.39, 3.57) 0.84 (0.07, 9.53) 1.11 (0.47, 2.61] Odds Ratio M-H. Fixed. 95% CI 2.11 (0.18, 25.35)	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajan M 2014 Bertani E 2011 Kong J 2013 Park JS 2011 Total evants Total evants Heterogenety: Chi ^p = Test for overall effect: Fileus Study or Subgroup Barnajan M 2014 Kong J 2013	Events 2 1 7 1 2.12, df = 3 Z = 0.25 (F RRC: Events 2 6	Total 20 52 165 52 289 3 (P = 1 P = 0.8 S Total 20 165	Events 0 2 6 2 0.55): l ² = 0) ORC: Events 1 1 4	Total 20 34 165 88 307 0% 5 <u>Total</u> 20 165	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4%	M-H. Fixed, 95% cf 5-54 (0.25, 123.08) 0.31 [0.03, 3-60] 1.17 [0.39, 3-57] 0.64 [0.07, 9.53] 1.11 [0.47, 2.61] 0.dds Ratio M-H. Fixed, 95% cf 2.11 [0.18, 25.36] 1.52 [0.42, 5.48]	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Jamajian M 2014 Jaentani E 2011 Kang J 2013 Park JS 2011 Total (99% C1) Total events Heterogeneity: Chi ^a = Teast for overall effect: Fileus Study or Subgroup Jamajian M 2014 Kang J 2013 Kin J 2014	Events 2 1 7 1 1 2.12, df = 5 Z = 0.25 (f RRC: <u>Events</u> 2	<u>Total</u> 20 52 165 52 289 3 (P = 1 P = 0.8 S <u>Total</u> 20	Events 0 2 6 2 10 0.55): I ² = 10) ORC: Events 1	Total 20 34 165 88 307 0% 5 <u>Total</u> 20	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7%	M-H. Fixed. 95% CI 5.54 (0.25, 123.08) 0.31 (0.03, 3.60) 1.17 (0.39, 3.57) 0.84 (0.07, 9.53) 1.11 (0.47, 2.61] Odds Ratio M-H. Fixed. 95% CI 2.11 (0.18, 25.35)	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Jamajian M 2014 Jentani E 2011 Card J 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP = Fetors for overall effect: Fileus Study or Subgroup Jamajian M 2014 Cang J 2013 Gui J 2014 Park JS 2011	Events 2 1 7 1 1 2.12, df = 3 Z = 0.25 (f RRC: <u>Events</u> 2 6 2 2	Total 20 52 165 52 289 3 (P = 1) P = 0.8 S Total 20 165 52 3 (P = 1) 0 105 106 52	Events 0 2 6 2 10 0.55): I ² = 0) ORC: Events 1 4 4	Total 20 34 165 88 307 0% 5 <u>Total</u> 20 165 114 88	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Jamajian M 2014 Jestanic E2011 Park JS 2011 Total (95% CI) Total (95% CI) Total events Heterogeneity: Chi ^p = rest for overall effect: Fileus Study or <u>Subgroup</u> Jamajian M 2014 Jamk JS 2011 Total (95% CI)	Eventa 2 1 7 1 2.12, df = 2 2 = 0.25 (f Eventa 2 6 2 2 1	Total 20 52 165 52 289 3 (P = 1 P = 0.8 S Total 20 165 108	Events 0 2 6 2 7 0 0.55): I ² = 00) ORC: <u>Events</u> 1 4 4 1	Total 20 34 165 88 307 0% 5 <u>Total</u> 20 165 114 88	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1%	MH-F. Fixed, 95% cf. 554 (0.25, 123.08) 0.31 (0.03, 360) 0.84 (0.07, 9.53) 1.11 [0.47, 2.61] 0.046 Ratio MH-Fixed, 95% cf. 2.11 [0.18, 22.36] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89]	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Jamajian M 2014 Jentani E 2011 Garda J 2013 Park JS 2011 Total (95% CI) Total owns Jearnagian M 2014 Ganagian M 2014 Ganagian M 2014 Arag J 2013 Gal 2013 Catal Genes S	Events 2 1 7 1 2 1 7 7 7 7 7 2 2 2 2 5 (F RRC: 2 2 6 2 2 1 1 1 1	Total 20 52 165 52 289 3 (P = 1) P = 0.8 S Total 108 52 345	Events 0 2 6 2 10 0.55); i ² = 10) ORC: Events 1 4 4 1	Total 20 34 165 88 307 0% Total 20 165 114 88 387	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl 0.01 0.1 1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl
Jamajian M 2014 Jestanic E 2011 Grad J 2013 Park JS 2011 Total (95% CI) Total vents Heterogeneity: Ch ² = Fileus <u>Bludy or Subgroup</u> Jamajian M 2014 Grad J 2014 Grad J 2014 Total (95% CI) Total (95% CI)	Events 2 1 7 1 1 2.12, df = (2 = 0.25 (f Events 2 6 2 1 1 1.30, df = (Total 20 52 165 52 289 3 (P = 1) P = 0.8 S Total 20 165 52 289 3 (P = 0.8) S Total 20 165 108 52 345 3 (P = 1)	Events 0 2 6 2 7 6 2 10 0.55): l ² = 10 0) 0 RC: Events 1 4 4 4 1 10 0.73); l ² =	Total 20 34 165 88 307 0% Total 20 165 114 88 387	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl
Jarnajian M 2014 Jertanic E2011 Caraj 2.2013 Park JS 2011 Total (95% CI) Catal (95% CI) Catal (95% CI) Catal 2.2013 Budy or Subgroup Budy or Subgroup Budy or Subgroup Budy or Subgroup Budy or Subgroup Catal (95% CI) Catal events Heterogeneity: Ch ² = Feat for overall effect:	Events 2 1 7 1 1 2.12, df = (2 = 0.25 (f Events 2 6 2 1 1 1.30, df = (Total 20 52 165 52 289 3 (P = 1) P = 0.8 S Total 20 165 52 289 3 (P = 0.8) S Total 20 165 108 52 345 3 (P = 1)	Events 0 2 6 2 7 6 2 10 0.55): l ² = 10 0) 0 RC: Events 1 4 4 4 1 10 0.73); l ² =	Total 20 34 165 88 307 0% Total 20 165 114 88 387	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl 0.01 0.1 1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl
Jamajian M 2014 Jentani E 2011 Caral 2013 Park JS 2011 Total rewnts Heterogeneity: ChP = E for overall effect: Fileus Study or Subgroup Study or Subgroup Park JS 2011 Park JS 2011 Total (9%) Ch Total 2014 Park JS 2011 Total rewnts Heterogeneity: ChP = Fest for overall effect:	Events 2 1 7 1 1 2.12, df = (2 = 0.25 (f Events 2 6 2 1 1 1.30, df = (Total 20 52 165 52 289 3 (P = 1) P = 0.8 S Total 20 165 52 289 3 (P = 0.8) S Total 20 165 108 52 345 3 (P = 1)	Events 0 2 6 2 7 6 2 10 0.55): l ² = 10 0) 0 RC: Events 1 4 4 4 1 10 0.73); l ² =	Total 20 34 165 88 307 0% Total 20 165 114 88 387	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl
Jarnajian M 2014 Jertanic E2011 Caraj 2.2013 Park JS 2011 Total (95% CI) Catal (95% CI) Catal (95% CI) Catal 2.2013 Budy or Subgroup Budy or Subgroup Budy or Subgroup Budy or Subgroup Budy or Subgroup Catal (95% CI) Catal events Heterogeneity: Ch ² = Feat for overall effect:	Events 2 1 7 1 1 2.12, df = (2 = 0.25 (f Events 2 6 2 1 1 1.30, df = (Total 20 52 165 52 289 3 (P = 0.8 3 (P = 0.8 108 52 345 3 (P = 1 P = 0.7	Events 0 2 6 2 10 0.55): ² = 10) ORC: Events 1 4 1 10 0.73): ² = '1)	Total 20 34 165 88 307 0% 5 <u>Total</u> 20 165 114 88 387 0%	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% CI 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 39, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% CI 2.11 [0, 14, 25, 36] 1.52 [0, 42, 548] 1.52 [0, 42, 2, 84] 1.52 [0, 42, 2, 84]	MH, Fixed, 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio MH, Fixed, 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS
Barnajian M 2014 Bertani E 2011 Yark JS 2013 Park JS 2011 Total (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: Tileus Study or <u>Subgroup</u> Barnajian M 2014 Barna J2013 Kim J 2013 Kim J 2014 Park JS 2011 Total (95% CI) Total (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: B bleeding	Eventa 2 1 7 1 1 2.12, df = 2 2 = 0.25 (F Eventa 2 6 2 1 1 1.30, df = 2 2 = 0.37 (F RRC:	Total 20 52 165 52 289 3 (P = 1 P = 0.8 S Total 20 165 108 52 345 3 (P = 1 P = 0.7 S	Events 0 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 0.0.55); i* = 10 0.73); i* = 10 0.73); i* = 11 0 0	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0%	4.4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 9.7% 41.4% 41.1% 7.8%	MH-F, Freed, 95% cf. 554 (0, 25, 123,08) 0.31 (0, 33, 860) 1.17 [0, 38, 357] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] MH-F, Freed, 95% cf. 2.11 [0, 18, 25, 36] 1.52 [0, 42, 5.48] 0.52 [0, 09, 2.89] 1.71 [0, 10, 27, 86]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Yarda 2013 Park JS 2011 Total (95% CI) Total events Heterogenetity: Ch ² = Test for overall effect: Fileus Study or <u>Subgroup</u> Barnajian M 2014 Park JS 2011 Total (95% CI) Total (95% CI) Total (95% CI) Total events Heterogenetic; Ch ² = Test for overall effect: B bleeding Study or <u>Subgroup</u> Barnajian M 2014	Eventa 2 1 7 1 2.12, df = 2 Z = 0.25 (f RRC: 2 6 2 2 6 2 1 1 1.30, df = 2 2 6 2 2 1 1 1.30, df = 2 7 2 6 2 1 1 1 2 2 1 2 1 2 3 2 1 2 3 2 3 2 3 2	Total 20 52 289 3 (P = 1 P = 0.8 5 Total 200 165 108 52 345 3 (P = 1 P = 0.7 345 3 (P = 1 P = 0.7 345 3 (P = 1 D = 0.7 5 20 20 20 20 20 20 20 20 20 20 5 2 289 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 6 6 2 10 0.55); I ² = Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 20 34 165 88 307 0% S Total 20 165 114 88 387 0% S Total 20 0%	4 4% 23.7% 57.4% 14.5% 100.0% <u>Weight</u> 100.0% <u>Weight</u> 16.1%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 360) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.64 [0.07, 9.53] 1.11 [0.47, 2.61] 0.64 [0.07, 9.53] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.77 [0.10, 27.86] 1.18 [0.49, 2.82] 0.64 Ratio M-H. Fixed, 95% CI 3.15 [0.12, 82, 16]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Jamajian M 2014 Jentani E 2011 Gard J 2013 Park JS 2011 Total (95% CI) Total oversil effect: Fleus Study or Subgroup Jamajian M 2014 Garaj 2013 Garajan M 2014 Park JS 2011 Total (96% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: is bleeding Study or Subgroup Jamajian M 2014 Garaj 2013	Events 2 1 7 1 2.12, df = 2 2 = 0.25 (f 2 2 1 1 1.30, df = 2 2 = 0.37 (f 2 2 1 1 1.30, df = 2 2 = 0.37 (f 2 2 1 1 1 2 2 1 1 2 2 1 2 1 2 1 2 1 2	Total 20 52 289 3 (P = 1 20 52 289 289 289 20 165 108 52 20 165 108 52 345 345 345 345 52 20 165 108 52 20 20 52 289 289 289 289 289 289 289 289 289 28	Events 0 2 2 6 6 2 10 0.55; I ⁴ = 10 0.55; I ⁴ = 2 0.55; I ⁴ = 1 4 4 4 1 1 1 1 0 0.73; I ⁴ = 2 0.55; I ⁴ = 2 0.55; I ⁴ = 2 10 0.05; I ⁴ = 2 0.55; I ⁴ = 2 0.05; I ⁴ = 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 20 34 165 88 307 0% 5 <u>Total</u> 20 165 387 0% 5 <u>Total</u> 20 0% 5 5 <u>Total</u> 20 165	4 4% 23.7% 7.4% 14.5% 100.0% Weight 100.0% Weight 100.0% Weight 16.1%	MH-F. Fixed, 95% CI 554 (0, 25, 123, 08) 0.31 (0, 03, 360) 1.17 [0, 39, 3.57] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] 0.44 [0, 07, 9.53] 1.11 [0, 47, 2.61] 0.44 [0, 47, 2.61] 1.11 [0, 47, 2.61] 0.45 [2, 04, 2, 48] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.18 [0, 49, 2.82] 0.46 Ratio MH-F. Fixed, 95% CI 3.15 [0, 12, 82; 16] 0.12 [8, 22; 41]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total revents Heterogeneity: ChP = Test for overall effect: = ileus Study or Subgroup Barnajian M 2014 Kang J 2013 Kind J 2014 Park JS 2011 Total (%% Ch) Total events Heterogeneity: ChP = Test for overall effect: is bleeding Study or Subgroup Barnajian M 2014 Kang J 2013	Eventa 2 1 7 1 2.12, df = 2 Z = 0.25 (f RRC: 2 6 2 2 6 2 1 1 1.30, df = 2 2 6 2 2 1 1 1.30, df = 2 7 2 6 2 1 1 1 2 2 1 2 1 2 3 2 1 2 3 2 3 2 3 2	Total 20 52 289 3 (P = 1 P = 0.8 5 Total 200 165 108 52 345 3 (P = 1 P = 0.7 345 3 (P = 1 P = 0.7 345 3 (P = 1 D = 0.7 5 20 20 20 20 20 20 20 20 20 20 5 2 289 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 6 6 2 10 0.55); I ² = Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 20 34 165 88 307 0% S Total 20 165 114 88 387 0% S Total 20 0%	4 4% 23.7% 7.4% 14.5% 100.0% Weight 100.0% Weight 100.0% Weight 16.1%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] Cdds Ratio M-H. Fixed, 95% CI 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.77 [0.10, 27.86] 1.18 [0.49, 2.82] 0.48 Ratio M-H. Fixed, 95% CI 3.15 [0.12, 82, 16]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total 99% CI) Total 99% CI) Total 99% CI) Total 90% CI Total 90% CI Total 90% CI Total 90% CI Total 90% CI Total 90% CI Barnajian M 2014 Ater J 2013 Park JS 2011 Total 90% CI Barnajian M 2014 Study or Subgroup Barnajian M 2014 Total 90% CI Total 90% CI Barnajian M 2014 Kang J 2013 Park JS 2011 Total 90% CI)	Events 2 1 7 7 1 1 2.12, df = 1 2 2 = 0.25 (F 2 2 = 0.25 (F 2 2 1 1 1.30, df = 1 2 2 = 0.37 (F 2 8 8 8 9 1 1 1 1 2 2 = 0.37 (F 2 2 2 2 2	Total 20 52 289 3 (P = 1 20 52 289 289 289 20 165 108 52 20 165 108 52 345 345 345 345 52 20 165 108 52 20 20 52 289 289 289 289 289 289 289 289 289 28	Events 0 2 6 2 10 0.55; ^μ = 0.55; ^μ = 0.55; ^μ = 1 1 4 4 4 4 1 10 0.73; ^μ = 10 0.73; ^μ =	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88	4 4% 23.7% 7.4% 14.5% 100.0% Weight 100.0% Weight 100.0% Weight 16.1%	MH-F. Fixed, 95% CI 554 (0, 25, 123, 08) 0.31 (0, 03, 360) 1.17 [0, 39, 3.57] 0.84 [0, 07, 9.53] 1.11 [0, 47, 2.61] 0.44 [0, 07, 9.53] 1.11 [0, 47, 2.61] 0.44 [0, 47, 2.61] 1.11 [0, 47, 2.61] 0.45 [2, 04, 2, 48] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.22 [0, 42, 54] 1.18 [0, 49, 2.82] 0.46 Ratio MH-F. Fixed, 95% CI 3.15 [0, 12, 82; 16] 0.12 [8, 22; 41]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total (95% CI) Total (96% CI)	Events 2 1 7 7 1 1 1 2.12, df = : 2 2 - 0.25 (F 2 2 6 6 2 1 1 1 1.30, df = : 1 2 2 - 0.25 (F 2 1 1 1 1.30, df = : 2 1 2 2 3 7 1 1 1 1 1 1 1 7 7 1 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 1 7 7 1 7 7 1 7 7 1 7 7 1 7	Total 200 52 165 52 289 3 (P = 0.8 52 201 165 52 345 3 (P = 0.7 345 3 (P = 0.7 345 3 (P = 0.7 20 165 52 2237	Events: 0 2 6 2 10 0.55); I ² = Events: 1 4 4 1 10 0.73); I ² = ORCC Events: 0 1 2 2 3 3	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	MH-F, Fixed, 95% Cf 554 (0, 25, 123, 08) 0, 31 (0, 03, 360) 1, 17 [0, 39, 3, 57] 0, 84 [0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 47, 2, 61] 1, 12 [0, 42, 34] 1, 12 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 18 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 23, 12, 59]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bernaji E 2011 Kang J 2013 Park JS 2011 Total vents Heterogeneity: Chi ⁹ = Total vents Total vents Heterogeneity: Chi ⁹ = Fileus Study or Subgroup Barnajian M 2014 Akang J 2013 Park JS 2011 Total vents Heterogeneity: Ch ⁹ = Test for overall effect Barnajian M 2014 Akang J 2013 Park JS 2011 Total vents Heterogeneity: Ch ⁹ = Barnajian M 2014 Kang J 2013 Park JS 2011 Total (95% CI) Total vents Heterogeneity: Ch ⁹	Events 2 1 7 7 1 1 2.12, df = 1 2 2 = 0.25 (F 2 2 = 0.25 (F 2 2 = 0.25 (T 2 2 = 0.37 (F 2 2 = 0.37 (F 2 2 = 0.37 (T 2 2 = 0.37 (T) 2 2 = 0.37 (T) 2 3 = 0.37	Total 200 52 165 52 289 3 (P = 0.8 52 70tal 165 108 52 345 108 52 345 108 52 345 108 52 345 108 52 20 165 52 20 20 165 52 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 2 6 2 2 10 0.55; I ⁴ = 0.55; I ⁴ = 0.55; I ⁴ = 1 4 4 4 4 1 1 0.073; I ⁴ = 1 2 0.073; I ⁴ = 1 2 0.073; I ⁴ = 1 2 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.073; I ⁴ = 1 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.073; I ⁴ = 1 0.075; I ⁴ =	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	MH-F, Fixed, 95% Cf 554 (0, 25, 123, 08) 0, 31 (0, 03, 360) 1, 17 [0, 39, 3, 57] 0, 84 [0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 47, 2, 61] 1, 12 [0, 42, 34] 1, 12 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 18 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 23, 12, 59]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100
Bernajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total vents Test for overall effect: F ileus <u>Study or Subgroup</u> Barnajian M 2014 Aran J 2013 Kim J 2014 Park JS 2011 Total (95% CI) Total vents Heterogenety: Ch ⁹ = Test for overall effect: S bleeding <u>Study or Subgroup</u> Barnajian M 2014 Aran J 2013 Park JS 2011 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI)	Events 2 1 7 7 1 1 2.12, df = 1 2 2 = 0.25 (F 2 2 = 0.25 (F 2 2 = 0.25 (T 2 2 = 0.37 (F 2 2 = 0.37 (F 2 2 = 0.37 (T 2 2 = 0.37 (T) 2 2 = 0.37 (T) 2 3 = 0.37	Total 200 52 165 52 289 3 (P = 0.8 52 70tal 165 108 52 345 108 52 345 108 52 345 108 52 345 108 52 20 165 52 20 20 165 52 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 2 6 2 2 10 0.55; I ⁴ = 0.55; I ⁴ = 0.55; I ⁴ = 1 4 4 4 4 1 1 0.073; I ⁴ = 1 2 0.073; I ⁴ = 1 2 0.073; I ⁴ = 1 2 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.073; I ⁴ = 1 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.072; I ⁴ = 1 0.073; I ⁴ = 1 0.075; I ⁴ =	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	MH-F, Fixed, 95% Cf 554 (0, 25, 123, 08) 0, 31 (0, 03, 360) 1, 17 [0, 39, 3, 57] 0, 84 [0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 47, 2, 61] 1, 12 [0, 42, 34] 1, 12 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 18 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 23, 12, 59]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS
Heterogeneity: ChP = Test for overall effect: F Ileus Study or Subgroup Barnajian M 2014 Kang J 2013 Kim J 2014 Park JS 2011 Total (95% CI) Total events Heterogeneity: ChP =	Events 2 1 7 7 1 1 2.12, df = 1 2 2 = 0.25 (F 2 2 = 0.25 (F 2 2 = 0.25 (T 2 2 = 0.37 (F 2 2 = 0.37 (F 2 2 = 0.37 (T 2 2 = 0.37 (T) 2 2 = 0.37 (T) 2 3 = 0.37	Total 200 52 165 52 289 3 (P = 0.8 52 70tal 165 108 52 345 108 52 345 108 52 345 108 52 345 108 52 20 165 52 20 20 165 52 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 2 6 2 2 10 0.55; I ⁴ = 0.55; I ⁴ = 0.55; I ⁴ = 1 4 4 4 4 1 1 0.073; I ⁴ = 1 0 0.73; I ⁴ = 1 2 0 0 0.73; I ⁴ = 2 2 1 0 0.55; I ⁴ = 2 0.55; I ⁵ = 2 0.55;	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	MH-F, Fixed, 95% Cf 554 (0, 25, 123, 08) 0, 31 (0, 03, 360) 1, 17 [0, 39, 3, 57] 0, 84 [0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 47, 2, 61] 1, 12 [0, 42, 34] 1, 12 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 18 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 23, 12, 59]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100
Bernajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total vents Test for overall effect: F ileus <u>Study or Subgroup</u> Barnajian M 2014 Aran J 2013 Kim J 2014 Park JS 2011 Total (95% CI) Total vents Heterogenety: Ch ⁹ = Test for overall effect: S bleeding <u>Study or Subgroup</u> Barnajian M 2014 Aran J 2013 Park JS 2011 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI)	Events 2 1 7 7 1 1 2.12, df = 1 2 2 = 0.25 (F 2 2 = 0.25 (F 2 2 = 0.25 (T 2 2 = 0.37 (F 2 2 = 0.37 (F 2 2 = 0.37 (T 2 2 = 0.37 (T) 2 2 = 0.37 (T) 2 3 = 0.37	Total 200 52 165 52 289 3 (P = 0.8 52 70tal 165 108 52 345 108 52 345 108 52 345 108 52 345 108 52 20 165 52 20 20 165 52 20 20 20 20 20 20 20 20 20 20 20 20 20	Events 0 2 2 6 2 2 10 0.55; I ⁴ = 0.55; I ⁴ = 0.55; I ⁴ = 1 4 4 4 4 1 1 0.073; I ⁴ = 1 0 0.73; I ⁴ = 1 2 0 0 0.73; I ⁴ = 2 2 1 0 0.55; I ⁴ = 2 0.55; I ⁵ = 2 0.55;	Total 20 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	MH-F, Fixed, 95% Cf 554 (0, 25, 123, 08) 0, 31 (0, 03, 360) 1, 17 [0, 39, 3, 57] 0, 84 [0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 07, 9, 53] 1, 11 [0, 47, 2, 61] 0, 44 (0, 47, 2, 61] 1, 12 [0, 42, 34] 1, 12 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 18 [0, 49, 2, 32] 0, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 12, 82] 0, 12 [0, 12, 82] 1, 12 [0, 23, 12, 59]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (99% CI) Total (99% CI) Total (99% CI) Total (90% CI) Total (90% CI) Total (90% CI) Total (99% CI) Total (99% CI) Total (99% CI) Total (99% CI) Total (90% CI)	Events 2 1 1 7 7 1 1 2.12, df = (2 2 6 2 2 6 2 2 1 1 1.0, df = (2 2 6 2 2 1 1 2 2 0.37 (f 1 2 2 0.37 (f 1 2 2 0.25 (f 1 1 7 7 1 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1	Total 200 52 165 52 289 P = 0.8 S Total 200 165 52 30 (P = 1 200 165 52 345 52 345 52 200 165 52 200 108 52 200 108 52 200 200 165 52 200 200 200 200 200 200 200	Events 0 2 6 6 2 10 0.55); l ⁴ = 1 0.55); l ⁴ = 1 4 4 7 1 0.73); l ⁴ = 1 0.73); l ⁴ = 2 0.55; l ² = 1 1 1 1 2 0.55; l ⁴ = 1 2 0.55; l ⁴ = 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 200 34 165 88 307 0% S Total 20 165 114 88 387 0% S Total 200 65 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% 41.4% 7.8% 100.0% 100.0%	M-H. Fixed, 95% CI 55 (4) (2,5, (2,2,08) 0,3) (10,3, 3,60) 1,17 (0,3, 3,57) 0,84 (0,07, 9,53) 1,11 (0,47, 2,61) 0,84 (0,07, 9,53) 1,11 (0,47, 2,61) 1,11 (0,47, 2,61) 1,52 (0,42, 5,48) 0,52 (0,09, 2,89) 1,57 (0,42, 5,48) 0,52 (0,09, 2,89) 1,71 (0,10, 27,86) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 1,18 (0,49, 2,82) 2,05 (0,52, 8,13)	M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS
Barnajan M 2014 Bernain E 2011 King J 2013 Park JS 2011 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (94% CI) Total (95%	Events 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 3 (P = 0.8 3 (P = 0.8 52 3 (P = 0.7 108 52 3 (P = 0.7 3 (P = 0.7 52 200 165 52 3 (P = 0.7 52 20 165 52 237 20 20 20 20 20 20 20 20 20 20	Events 0 2 2 6 2 2 6 2 2 6 2 2 6 2 7 0 0 0 0 55); I ⁴ = 1 0 0 0 7 3; I ⁴ = 1 0 0 0, 55); I ⁴ = 2 7 2 6 2 7 7 8 9 7 8 9 7 8 9 8 9 8 9 8 9 8 9 8 9	Total 200 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% 100.0% Weight 100.0% Weight 16.1% 49.6%	MH-F. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 360) 1.17 [0.38, 357] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.44 [0.07, 9.53] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 0.49 [2.12] 0.49 [2.12] 0.4	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bernaji E 2011 Kang J 2013 Park JS 2011 Total (95% CI) Total (95	Events 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 3 (P = 20 165 52 20 165 52 20 165 52 3 (P = P = 0.8 52 3 (P = P = 0.8 52 20 165 52 20 20 165 52 20 20 20 20 20 20 20 20 20 2	Events 0 2 6 6 2 10 0.55); ⁽⁾ = 1 0.55); ⁽⁾ = 1 4 4 1 1 4 1 0.73); ⁽⁾ = 2 0.73); ⁽⁾ = 2 0.73; ⁽⁾ = 1 0.73; ⁽⁾ = 2 0.73; ⁽⁾ = 1 0.73; ⁽⁾ = 1 0.73; ⁽⁾ = 2 0.73; ⁽⁾ = 1 0.73; ⁽⁾ = 1 0.75; ⁽⁾ = 1	Total 200 34 165 88 307 0% S Total 200 165 114 88 387 0% S Total 200 165 114 88 200 68 207 30%	4 4% 23.7% 57.4% 14.5% 100.0% 97% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 49.6% 100.0% Weight	MH-F. Fixed, 95% Cf 554 (0.25, 123,08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.41 [0.47, 2.61] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 0.52 [0.09, 2.89] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.71 [0.10, 27.86] 1.72 [0.23, 12.59] 2.05 [0.52, 8.13] 0.055 [0.52, 8.13] 0.055 [0.52, 8.13]	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Barnajia M 2014 Kang J 2013 Park JS 2011 Total genetic Fileus Study or Subgroup Barnajian M 2014 Kang J 2013 Kang J 2013 Chal events Heterogeneity: Chi ^a = Test for overall effect: 3 bleeding Study or Subgroup Barnajian M 2014 Park JS 2011 Total (95% CI) Total Gyents Heterogeneity: Chi ^a = Test for overall effect: 3 bleeding Study or Subgroup Park JS 2011 Total Gyents Heterogeneity: Chi ^a = Test for overall effect: 4 urinary retention Study or Subgroup	Events 2 1 1 7 7 1 1 2.12, df = 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 3 (P = 0.8 3 (P = 0.8 52 3 (P = 0.7 108 52 3 (P = 0.7 3 (P = 0.7 52 200 165 52 3 (P = 0.7 52 20 165 52 237 20 20 20 20 20 20 20 20 20 20	Events 0 2 6 6 2 10 0.55); ^(r) = 1 0.55); ^(r) = 1 4 4 1 1 0.73); ^(r) = 1 0.73); ^(r) = 2 0.73; ^(r) = 1 0.073; ^(r) = 2 0.073; ^(r) = 1 0.073; ^(r) = 1 0.075; ^(r)	Total 200 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 20 165 88 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% Weight 16.1% 49.6% 100.0% Weight 16.1% 35.1%	MH-F. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 360) 1.17 [0.38, 357] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.44 [0.07, 9.53] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 0.49 [2.12] 0.49 [2.12] 0.4	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total (99% CI) Total (99% CI) Total (99% CI) Total (90% CI) Total (90% CI) Total (90% CI) Total (99% CI) Total (99% CI) Total (99% CI) Total (99% CI) Total (90% CI)	Events 2 1 7 7 1 1 1 2.12, df = : 2 2 = 0.25 (F 2 2 6 6 2 1 1 1.30, df = : 2 6 6 2 1 1 1.30, df = : 2 2 = 0.25 (F 2 1 1 1.30, df = : 2 0 5 1 1 1.30, df = : 2 0 2 1 1 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 200 2289 3 (P = 1) 289 3 (P = 1) 20 165 52 289 3 (P = 1) 20 165 52 3 (P = 1) 20 165 52 3 (P = 0.7) 165 52 237 2 (P = 1) 20 3 (P = 0.3) 165 52 237 2 (P = 0.3) 8 Total 20	Events 0 2 2 6 6 2 2 10 0 0 55; l ² = 1 1 4 4 4 1 1 0 0,55; l ² 2 2 0,05; l ² 2 2 0,05; l ² 2 2 0,05; l ² 2 2 2 0,05; l ² 2 2 2 0,05 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 34 165 88 307 0% Total 20 165 114 88 387 0% 5 Total 20 0% 5 Total 20 0% 5 Total 20 0% 5 Total 20 0%	4 4% 4 4% 574% 574% 14.5% 100.0% Weight 100.0% Weight 100.0% Weight 35.1% 20.5%	M-H. Fixed, 95% CI 5 54 (0.2, 5, 123,08) 0.31 (0.3, 360) 1.17 [0.33, 357] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.44 [0.07, 9.53] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 0.44 Ratio M-H. Fixed, 95% CI 3.15 [0.12, 82.16] 2.01 [0.18, 22.41] 2.05 [0.52, 8.13] 0.45 [0.52, 8.13]	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total revents Heterogenetry: ChP = Test for overall effect: Fileus Study or Subgroup Barnajian M 2014 Kang J 2013 Kin J 2014 Park JS 2011 Total (%CI) Total events Heterogenetry: ChP = Test for overall effect: 3 bleeding Study or Subgroup. Total (%CI) Total events Heterogenetry: ChP = Test for overall effect: 3 bleeding Study or Subgroup. Total events Heterogenetry: ChP = Test for overall effect: 4 urinary retention Study or Subgroup. Barnajian M 2014 Heterogenetry: ChP = Test for overall effect: 4 urinary retention Study or Subgroup. Barnajian M 2014 Park JS 2011 Total events Heterogenetry: ChP = Test for overall effect:	Events 2 1 1 7 7 1 1 2.12, df = (2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 3 (P = 1, P = 0.8 S Total 108 52 3 (P = 1, P = 0.8 S Total 20 165 52 23 3 (P = 1, P = 0.8 S Total 20 165 52 20 20 165 52 20 20 165 52 20 20 20 165 52 20 20 20 165 52 20 20 20 165 52 20 20 20 20 20 20 20 20 20 2	Events 0 2 6 6 2 10 0.55); ⁽⁾ = Events 1 4 4 1 1 0.73); ⁽⁾ = Events 0 1 2 0.73; ⁽⁾ = 3 0.55; ⁽⁾ = 1 1 0 0.73; ⁽⁾ = 1 2 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0 0 0.73; ⁽⁾ = 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 200 34 165 88 307 0% <u>Total</u> 200 5 114 88 387 0% 5 <u>Total</u> 200 5 5 <u>Total</u> 200 5 88 273 0% 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	4 4% 23.7% 57.4% 14.5% 100.0% 97% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 49.6% 100.0% Weight 100.0%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.41 [0.47, 2.61] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 2.05 [0.52, 8.13] 2.05 [0.52, 8.13] 0.dds Ratio M-H. Fixed, 95% CI 0.03 [0.01, 8, 224] 1.29 [0.08, 2129] 0.33 [0.02, 7.00]	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Barnajian M 2014 Bertani E 2011 Kang J 2013 Park JS 2011 Total revents Heterogenetry: ChP = Test for overall effect: Fileus Study or Subgroup Barnajian M 2014 Kang J 2013 Kin J 2014 Park JS 2011 Total (%CI) Total events Heterogenetry: ChP = Test for overall effect: S bleeding Study or Subgroup Dark JS 2011 Total (%CI) Total (%CI) Total events Heterogenetry: ChP = Test for overall effect: S bleeding Study or Subgroup Total events Heterogenetry: ChP = Test for overall effect: 4 urinary retention Study or Subgroup Dark JS 2011 Total (%CI) Total events Heterogenetry: ChP = Test for overall effect:	Events 2 1 1 7 7 1 1 2.12, df = (2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 3 (P = P = 0.8 S Total 20 165 52 3 (P = 20 165 52 3 (P = 20 165 52 3 (P = P = 0.8 S Total 20 20 165 52 20 3 (P = P = 0.8 S Total 20 20 20 20 20 20 20 20 20 20	Events 0 2 6 6 2 10 0.55); ⁽⁾ = Events 1 4 4 1 1 0.73); ⁽⁾ = Events 0 1 2 0.73; ⁽⁾ = 3 0.55; ⁽⁾ = 1 1 0 0.73; ⁽⁾ = 1 2 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0.73; ⁽⁾ = 1 0 0 0.73; ⁽⁾ = 1 0 0 0 0.73; ⁽⁾ = 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total 200 34 165 88 307 0% <u>Total</u> 200 5 114 88 387 0% 5 <u>Total</u> 200 5 5 <u>Total</u> 200 5 88 273 0% 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	4 4% 4 4% 574% 574% 14.5% 100.0% Weight 100.0% Weight 100.0% Weight 35.1% 20.5%	MH-F. Fixed, 95% CT 55 (4) (2,5, (2,2,08) 0,31 (10,3,360) 1,17 [0,33,357] 0,84 [0,07,9,53] 1,11 [0,47,2,61] Odds Ratio MH-F. Fixed, 95% CT 1,52 [0,42,5,48] 0,52 [0,09,2,89] 1,52 [0,42,5,48] 0,52 [0,09,2,89] 1,71 [0,10,27,86] 1,18 [0,49,2,82] 1,18 [0,49,2,82] 0,52 [0,09,2,89] 2,05 [0,52,8,13] Odds Ratio MH-F. Fixed, 95% CT 0,32 [0,01,8,22] 0,05 [0,52,8,13] Odds Ratio MH-F. Fixed, 95% CT 0,32 [0,01,8,22]	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
Aranajan M 2014 Jertani E 2011 Grad J 2013 Park JS 2011 Total (95% CI) Grad avents Jearoganety: ChP = Fest for overall effect: illeus <u>Budy or Subgroup</u> Aranajan M 2014 Grad 2013 Ordal events Heterogeneity: ChP = Fest for overall effect: bleeding <u>Budy or Subgroup</u> Aranajan M 2014 Grad events Heterogeneity: ChP = Fest for overall effect: bleeding <u>Budy or Subgroup</u> <u>Budy or Subgro</u>	Events 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 70 165 108 52 200 165 108 52 3 (P = 1 200 165 52 237 7 otal 165 52 207 165 52 207 165 52 208 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 207 108 52 207 108 52 207 108 52 207 108 108 52 207 108 108 108 108 108 108 108 108	Events 0 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 200 6 88 273 0% 5 Total 200 6 88 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% 97% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 49.6% 100.0% Weight 100.0%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.41 [0.47, 2.61] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 2.05 [0.52, 8.13] 2.05 [0.52, 8.13] 0.dds Ratio M-H. Fixed, 95% CI 0.03 [0.01, 8, 224] 1.29 [0.08, 2129] 0.33 [0.02, 7.00]	MHL Fixed, 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio MHL Fixed, 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio MHL Fixed, 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio MHL Fixed, 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS
majian M 2014 majia M 2011 rdani E 2011 rdani E 2011 rdani E 2011 rdani E 2011 rdani E 2013 rdani E 2013 rdani E 2013 rdani E 2014 rdy or Subgroup rdani M 2014 rdy J 2013 rd 2013 rd 2013 rd 2014 rd 32 2011 rdani e 2014 rd 32 2011 rdani e 2015 rdani	Events 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 70 165 108 52 200 165 108 52 3 (P = 1 200 165 52 237 7 otal 165 52 207 165 52 207 165 52 208 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 207 108 52 207 108 52 207 108 52 207 108 108 52 207 108 108 108 108 108 108 108 108	Events 0 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 200 6 88 273 0% 5 Total 200 6 88 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% 97% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 49.6% 100.0% Weight 100.0%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.41 [0.47, 2.61] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 2.05 [0.52, 8.13] 2.05 [0.52, 8.13] 0.dds Ratio M-H. Fixed, 95% CI 0.03 [0.01, 8, 224] 1.29 [0.08, 2129] 0.33 [0.02, 7.00]	M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio 0.01 0.1 10 100 Favours RRCS Favours ORCS Odds Ratio
majian M 2014 tani E 2011 ng J 2013 rk JS 2011 tal events terogeneity: ChP = st for overall effect: eus udy or Subgroup majian M 2014 ng J 2013 n J 2014 rk JS 2011 tal events terogeneity: ChP = st for overall effect: bleeding udy or Subgroup ngjain M 2014 ng J 2013 rk JS 2011 tal (95% CI) tal events terogeneity: ChP = st for overall effect: bleeding udy or Subgroup rajain M 2014 ng J 2013 rk JS 2011 tal (95% CI) tal events terogeneity: ChP = st for overall effect: udy or Subgroup at option overall effect: udy or Subgroup at 2013 rnajar M 2014 ng J 2013 rth JS 2011 tal (95% CI) tal events terogeneity: ChP = st for overall effect: tal events	Events 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 52 165 52 289 70 165 108 52 200 165 108 52 3 (P = 1 200 165 52 237 7 otal 165 52 207 165 52 207 165 52 208 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 200 165 52 207 108 52 207 108 52 207 108 52 207 108 108 52 207 108 108 108 108 108 108 108 108	Events 0 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 200 34 165 88 307 0% 5 Total 20 165 114 88 387 0% 5 Total 200 6 88 273 0% 5 Total 200 6 88 273 0%	4 4% 23.7% 57.4% 14.5% 100.0% 97% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 41.4% 49.6% 100.0% Weight 100.0%	M-H. Fixed, 95% CI 554 (0.25, 123.08) 0.31 (0.03, 860) 1.17 [0.38, 3.57] 0.84 [0.07, 9.53] 1.11 [0.47, 2.61] 0.41 [0.47, 2.61] 1.11 [0.47, 2.61] 1.11 [0.47, 2.61] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.52 [0.42, 5.48] 0.52 [0.09, 2.89] 1.71 [0.10, 27.86] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 1.18 [0.49, 2.82] 2.05 [0.52, 8.13] 2.05 [0.52, 8.13] 0.dds Ratio M-H. Fixed, 95% CI 0.03 [0.01, 8, 224] 1.29 [0.08, 2129] 0.33 [0.02, 7.00]	M-H. Fixed. 95% Cl 0.01 0.1 1 0 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 10 100 Favours RRCS Favours ORCS Odds Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 10 100 Favours RRCS Favours ORCS

Figure 3. Meta-analysis of postoperative complications associated with robotic-assisted rectal cancer surgery versus open rectal cancer surgery. (A) overall postoperative complications, (B) postoperative mortality, (C) anastomotic leakage, (D) wound infection, (E) pelvic abscess, (F) ileus, (G) bleeding, (H) urinary retention.

A length of stay

	F	RCS		0	ORCS			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	CI IV. Random, 95% CI
Barnajian M 2014	6	6.75	20	7	3.25	20	9.3%	-1.00 [-4.28, 2.28]	
Bertani E 2011	6	12	52	7	5.1	34	8.2%	-1.00 [-4.68, 2.68]	
Desouza AL 2011	7	5.8	36	7.3	4.1	46	13.1%	-0.30 [-2.53, 1.93]	
Ghezzi TL 2014	6	0.5	65	9	0.3	109	20.0%	-3.00 [-3.13, -2.87]	
Kang J 2013	10.8	5.5	165	16	8.6	165	15.9%	-5.20 [-6.76, -3.64]	
Kim J 2014	7	1.8	108	7.6	2.8	114	19.3%	-0.60 [-1.22, 0.02]	1
Park JS 2011	10.4	4.7	52	12.8	7.1	88	14.2%	-2.40 [-4.36, -0.44]	i ——
Total (95% CI)			498			576	100.0%	-2.10 [-3.47, -0.73]	◆
Heterogeneity: Tau ² =	2.45; Cł	ni² = 7'	1.82, df	= 6 (P	< 0.00	001); l²	= 92%		-10 -5 0 5 10
Test for overall effect:	Z = 3.00) (P = (0.003)						-10 -5 0 5 10 Favours RRCS Favours ORCS

B pain score

	R	RCS		0	RCS			Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI		IV. Rai	ndom. 9	5% CI		
Kim J 2014	4.5	1.8	108	4.5	2	114	49.4%	0.00 [-0.50, 0.50]						
Park JS 2011	5.2	1.2	52	6.4	1.3	88	50.6%	-1.20 [-1.62, -0.78]						
Total (95% CI)			160			202	100.0%	-0.61 [-1.78, 0.57]						
Heterogeneity: Tau ² =				df = 1 (P	= 0.	0003);	l² = 92%		-4	-2		2	4	
Test for overall effect: Z = 1.01 (P = 0.31)										Favours RRC	SFave	ours OR	cs	

C flatus passage

	F	RCS		0	RCS			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% CI	IV. Fixed, 95% CI
Barnajian M 2014	3	1.75	20	4	1.5	20	0.8%	-1.00 [-2.01, 0.01]	
Bertani E 2011	2	1	52	3	2	34	1.5%	-1.00 [-1.73, -0.27]	
Ghezzi TL 2014	2	0.17	65	3	0.5	109	74.6%	-1.00 [-1.10, -0.90]	—
Kang J 2013	2.2	1.1	165	3	1.4	165	10.6%	-0.80 [-1.07, -0.53]	*
Kim J 2014	1.8	0.9	108	2.7	1.1	114	11.3%	-0.90 [-1.16, -0.64]	-
Park JS 2011	3.2	1.8	52	4.4	3	88	1.2%	-1.20 [-2.00, -0.40]	
Total (95% CI)			462			530	100.0%	-0.97 [-1.06, -0.88]	•
Heterogeneity: Chi ² = 2	2.43, df	= 5 (P	= 0.79)	; l ² = 09	6			-	-4 -2 0 2 4
Test for overall effect:	Z = 21.4	6 (P <	0.0000	01)					Favours RRCS Favours ORCS

D Time to resume diet

	F	RCS		c	ORCS			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Barnajian M 2014	4	1.75	20	4.5	1.75	20	19.5%	-0.50 [-1.58, 0.58]	
Bertani E 2011	2	3.06	52	3	2.55	34	19.1%	-1.00 [-2.19, 0.19]	
Ghezzi TL 2014	1	0.17	65	5	0.33	109	21.4%	-4.00 [-4.07, -3.93]	•
Kang J 2013	4.5	1.9	165	6.4	2.5	165	21.0%	-1.90 [-2.38, -1.42]	
Park JS 2011	6.7	3.8	52	7.6	3.3	88	19.0%	-0.90 [-2.14, 0.34]	
Total (95% CI)			354			416	100.0%	-1.71 [-3.31, -0.12]	
Heterogeneity: Tau ² =	3.11; Cł	ni² = 1	56.56, 0	if = 4 (P	< 0.0	0001);	² = 97%	-	
Test for overall effect:	Z = 2.10	(P = (0.04)						-4 -2 0 2 4 Favours RRCS Favours ORCS

Figure 4. Meta-analysis of outcomes between robotic-assisted rectal cancer surgery and open rectal cancer surgery. (A) length of stay, (B) pain score, (C) flatus passage, (D) time to diet resumption.

Meta-analysis of the pathological details. Kang *et al.*²⁶ and Park *et al.*²⁸ described proximal margin indices, and the combined data indicated no differences in this parameter (MD: 2.23, 95% CI: -1.19 to 5.65; P = 0.20, $I^2 = 88$) (Fig. 5A). Six studies reported distal margins^{22,23,25-28}, and there was no difference between the two groups in this parameter (MD: 0.17, 95% CI: -0.14 to 0.48; P = 0.27) (Fig. 5B), but there was significant heterogeneity (P = 0.0003, $I^2 = 79$). Two studies mentioned circumferential resection margins^{22,28}, and the pooled data revealed no significant differences (MD: -0.22, 95% CI: -1.82 to 1.38, P = 0.79) (Fig. 5C).

All the included studies reported the number of retrieved lymph nodes^{22–28}. The combined data indicated that the two groups did not differ significantly in this parameter (MD: 1.49, 95% CI: -0.82 to 3.79; P=0.21) (Fig. 5D), and there was significant heterogeneity (P < 0.00001, $I^2 = 79$). Moreover, the pooled data showed no significant differences in the number of retrieved positive lymph nodes between the two groups (MD: 0.07, 95% CI: -0.29 to 0.44, P=0.70) (Fig. 5E).

Long-term outcomes. *Disease-free survival (DFS).* Two studies reported DFS outcomes^{25,28}. Kang *et al.* reported that the 2-year DFS was 83.5% in the RRCS group and 79.7% in the ORCS group. Ghezzi *et al.*²⁵ reported that the 5-year DFS was 73.2% and 69.5% in the RRCS and ORCS groups, respectively. The combined data indicated no differences in DFS between the two arms (HR: 0.84, 95% CI: 0.53–1.35, P=0.47) and no heterogeneity (P=0.87, $I^2=0$) (Fig. 6).

A proximal margin

	RRCS ORCS Mean SD Total Mean SD Tota							Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, R	andom, 95	% CI		
Kang J 2013	12	4.9	165	11.4	5.5	165	53.5%	0.60 [-0.52, 1.72]						
Park JS 2011	16.5	6	52	12.4	6.6	88	46.5%	4.10 [1.96, 6.24]				-		
Total (95% CI)			217			253	100.0%	2.23 [-1.19, 5.65]						
Heterogeneity: Tau ² = Test for overall effect:				= 1 (P	= 0.0	04); ² =	= 88%		-10	-5 Favours RR	0 CS Favou	5 JITS ORCS	10	

B distal margin

	F	RCS		0	RCSn			Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95%	CI
Barnajian M 2014	2.05	1.13	20	2.05	1.1	20	11.3%	0.00 [-0.69, 0.69]		
Bertani E 2011	2.6	1.76	52	2.6	2.02	34	9.1%	0.00 [-0.83, 0.83]		_
Ghezzi TL 2014	2.7	0.47	65	2.2	0.25	109	24.7%	0.50 [0.38, 0.62]	-	
Kang J 2013	1.9	1.4	165	2.2	1.7	165	19.8%	-0.30 [-0.64, 0.04]		
Kim J 2014	1.4	1	108	1.2	0.9	114	22.0%	0.20 [-0.05, 0.45]		
Park JS 2011	2.8	1.9	52	2.3	1.5	88	13.1%	0.50 [-0.10, 1.10]		
Total (95% CI)			462			530	100.0%	0.17 [-0.14, 0.48]	-	
Heterogeneity: Tau ² =	0.10; Cł	ni² = 23	3.29, df	= 5 (P	= 0.00	03); l² =	= 79%		-2 -1 0	
Test for overall effect:	Z = 1.09) (P = (0.27)						Favours RRCS Favours	ORCS

C circumferential resection margin

	F	RRCS		0	RCS			Mean Difference		Me	an Differend	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV.	Fixed, 95%	CI	
Barnajian M 2014	10.5	7.25	20	8	7.5	20	12.2%	2.50 [-2.07, 7.07]					
Park JS 2011	7.9	4.5	52	8.5	5.7	88	87.8%	-0.60 [-2.31, 1.11]					
Total (95% CI)			72			108	100.0%	-0.22 [-1.82, 1.38]			-		
Heterogeneity: Chi ² = Test for overall effect:		•		; I ² = 35	5%				-10	-5 Favours R	0 RCS Favou	5 JITS ORCS	10

D retrieved lymph nodes

	RRCS			ORCS				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	CI IV, Random, 95% CI			
Barnajian M 2014	14	4.75	20	12	4	20	14.8%	2.00 [-0.72, 4.72]	g +			
Bertani E 2011	20.5	9.69	52	16	10.2	34	11.3%	4.50 [0.18, 8.82]				
Desouza AL 2011	15	7.8	36	16.8	6.6	46	13.8%	-1.80 [-4.98, 1.38]				
Ghezzi TL 2014	20.1	10.3	65	14.1	6.2	109	14.8%	6.00 [3.24, 8.76]	j —			
Kang J 2013	15	9.4	165	17.4	10.9	165	16.0%	-2.40 [-4.60, -0.20]	ı —			
Kim J 2014	18.6	7.2	108	16.7	7.9	114	16.4%	1.90 [-0.09, 3.89]	n –			
Park JS 2011	19.4	10.2	52	18.5	10.9	88	12.9%	0.90 [-2.69, 4.49]	n			
Total (95% CI)			498			576	100.0%	1.49 [-0.82, 3.79]				
Heterogeneity: Tau ² = 7.40; Chi ² = 28.41, df = 6 (P < 0.0001); l ² = 79%									-10 -5 0 5 10			
Test for overall effect: Z = 1.26 (P = 0.21)									Favours RRCS Favours ORCS			

E positive lymph nodes

	RRCS			ORCS				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl		
Bertani E 2011	0	3.12	52	0	3.12	34	7.3%	0.00 [-1.35, 1.35]			
Kang J 2013	1	2.3	165	1.3	3.2	165	36.7%	-0.30 [-0.90, 0.30]			
Kim J 2014	1.3	3.1	108	0.6	1.4	114	32.6%	0.70 [0.06, 1.34]			
Park JS 2011	1.1	2	52	1.3	2.5	88	23.4%	-0.20 [-0.95, 0.55]			
Total (95% CI)			377			401	100.0%	0.07 [-0.29, 0.44]	-		
Heterogeneity: Chi ² = 5.70, df = 3 (P = 0.13); $ ^2 = 47\%$											
Test for overall effect:	Z = 0.38	s (P = 0	Favours RRCS Favours ORCS								

Figure 5. Meta-analysis of the pathological details between robotic-assisted rectal cancer surgery and open rectal cancer surgery. (A) proximal margin, (B) distal margin, (C) circumferential resection margin, (D) retrieved lymph nodes, (E) positive lymph nodes.

Overall survival. Ghezzi *et al.*²⁵ reported that the 5-year overall survival rate was higher in the RRCS group than the ORCS group, but this difference was not significant (85.0% vs. 76.1%). Future studies should be conducted to assess this index.

Publication bias. A funnel plot analysis of all studies was performed in the meta-analysis of overall postoperative complications between RRCS and ORCS. Visually, all of the studies were within the limits of the 95% CIs (Fig. 7). Moreover, the statistical test indicated no evidence of publication bias (Egg's test P = 0.174, Begg's test P = 0.764).




Figure 6. Meta-analysis of disease-free survival in the robotic-assisted rectal cancer surgery group compared with the open rectal cancer surgery group.




Figure 7. Funnel plot of overall postoperative complications associated with robotic-assisted rectal cancer surgery compared with open rectal cancer surgery.

Sensitivity analysis. A sensitivity analysis was performed by excluding the studies with a low quality score (Score ≤ 6)^{27,28}. The results were not influenced, with the exception of the time to flatus passage. The results are listed in Table 2.

Discussion

Several meta-analyses have evaluated the efficacy and safety of robotic-assisted surgery versus open surgery in gastric cancer^{29,30}, pancreatic disease³¹, renal disease³², and bladder cancer³³. All of these studies have indicated that robotic-assisted surgery is safe and effective. However, no meta-analysis has been conducted to evaluate robotic-assisted surgery compared with open surgery for rectal cancer.

This meta-analysis assessed the efficacy and safety of RRCS versus ORCS. This meta-analysis indicated that RRCS may provide certain benefits over ORCS. Compared with ORCS, RRCS is associated with a lower EBL (MD: -139.98, 95% CI: -159.11 to -120.86; P < 0.00001), shorter LOS (MD: -2.10, 95% CI: -3.47 to -0.73; P = 0.003), less intraoperative transfusion requirements (OR: 0.52, 95% CI: 0.28 to 0.99, P = 0.05), shorter time to flatus passage (MD: -0.97, 95% CI = -1.06 to -0.88, P < 0.00001), and shorter time to diet resumption (MD: -1.71.95% CI = -3.31 to -0.12, P = 0.04). There were no significant differences in overall postoperative complications, anastomotic leakage, pain scores, wound infection, ileus, pelvic abscess, bleeding, urinary retention, postoperative mortality, proximal margin, distal margin, circumferential resection margin, number of lymph nodes retrieved, DFS, and overall survival between the two groups. However, the disadvantage of RRCS is that it was associated with a longer operative time (MD: -139.98, 95% CI: -159.11 to -120.86; P < 0.00001).

The combined data indicated that compared with the ORCS group, the EBL was significantly lower in the RRCS group. Due to a lower EBL, it is possible to suggest that RRCS may significantly reduce the probability of transfusion. Indeed, our meta-analysis suggested that the transfusion rate was significantly lower in the RRCS group compared with the ORCS group. Thus, reduced transfusion rates may prevent the recurrence of cancer³⁴. Patients with cancer who receive more intraoperative blood transfusions are at greater risk for cancer recurrence, and the volume of transfused blood at surgery is an independent risk factor for cancer recurrence³⁵. In addition, more EBL may indicate an unfavorable prognosis of patients with cancer^{36,37}.

Another advantage of RRCS is its associated shorter LOS. The shorter LOS may be explained by the following rationale: RRCS is a minimally invasive surgery, and it may provide faster wound recovery and reduce postoperative pain. RRCS has a shorter time to flatus passage and a faster recovery to normal diet resumption.

The overall complication rate was similar between the two techniques (7% in the RRCS group and 8% in the ORCS group). This finding also indicated that RRCS is as safe and feasible as ORCS. The most frequently occurring events included anastomotic leakage, wound infection, ileus, and pelvic abscess. Our analysis indicated that the two groups had no differences in those regards.

	No.	Patient		Effect	Analysis			Heterogeneity	
Outcome	study	RRCS	ORCS	measure	model	Effect and its 95% CI	P value	I ² (%)	Р
Operative time	5	338	374	MD	RE	68.47 (43.29,93.64)	< 0.00001	71	0.0007
LOS	5	338	374	MD	RE	-2.52 (-4.08,-0.95)	0.002	75	0.003
Overall postoperative complications	5	338	374	OR	FE	0.93 (0.67,1.30)	0.68	0	0.42
Time to flatus passage	4	302	328	MD	FE	-0.98 (-1.07,-0.88)	0.00001	0	0.61
Time to resumption of a normal diet	4	302	328	MD	RE	-1.91 (-3.64,-0.17)	0.03	98	< 0.00001
Anastomotic leakage	5	338	374	OR	FE	1.80 (0.94,3.46)	0.10	0	0.89
Wound infection	3	253	245	OR	RE	0.42 (0.03,5.05)	0.49	75	0.02
Pelvic abscess	3	237	219	OR	FE	1.16 (0.46,2.90)	0.75	4	0.35
Retrieved lymph nodes	5	338	374	MD	RE	1.55 (-1.88,4.99)	0.38	86	< 0.00001
Distal margin	4	302	328	MD	RE	0.07 (-0.45,0.60)	0.78	86	< 0.0001
Ileus	2	185	185	OR	FE	1.63 (0.52,5.09)	0.40	0	0.82
Urinary retention	2	56	66	OR	FE	0.67 (0.09,5.17)	0.70	0	0.52
Bleeding	2	185	185	OR	FE	2.38 (0.35,16.38)	0.38	0	0.83
Retrieved positive lymph nodes	2	217	199	MD	FE	-0.25 (-0.80,0.30)	0.37	0	0.69

Table 2. Sensitivity analyses excluding the low-quality studies.RRCS: robotic-assisted rectal cancer surgery,ORCS: open rectal cancer surgery,MD: mean difference,OR: odds ratio;FE: fixed-effects model;RE: randomeffects model.

.....

Anastomotic leakage is a major surgical complication of gastrointestinal surgery²⁹, and it represents one of the most dreaded complications of colorectal cancer. The mortality rate is high in patients with colorectal anastomotic leakage that required re-operation and accounts for almost 40% of the deaths after colorectal cancer surgery²⁹. The anastomotic leakage rate was 6.49% (31/478) in the RRCS group and 4.5% (25/556) in the ORCS group, which was not a significant difference. The rate (6.49%) was consistent with previous reports for robotic surgery (1.8–12.1%)^{5,38,39} and was similar to the rate of 7% that was reported in open rectal cancer surgery based on a multicenter randomized controlled trial⁴⁰.

The present study revealed no difference in oncologic clearance (proximal margin, circumferential resection margin, distal margin, and number of retrieved lymph nodes). Resection margins and number of retrieved lymph nodes have been regarded as quality indicators in rectal cancer surgery⁴¹ because the distal margin, circumferential resection margin, and number of retrieved lymph nodes were important parameters for the evaluation of prognosis in rectal cancer^{42–45}. Several studies have indicated that RRCS can achieve good-quality performance.

The long-term follow-up was reported in two studies. The results indicated that there was no difference in DFS or overall survival between the two groups. Hara *et al.* reported that the 5-year overall survival and DFS rates were 88.6% and 76.6%, respectively, for patients diagnosed with stage III rectal cancer who had undergone robotic surgery⁷. The 3-year overall survival rate was 97%⁴⁶.

Robotic rectal cancer surgery can achieve promising survival rates. Due to the limited number of studies, more studies are mandatory to establish the value of robotic surgery for rectal cancer in the future.

We should note the disadvantage of RRCS, namely, it requires a longer operative time compared with ORCS. This result is mainly attributed to the docking and preparation times associated with RRCS. A previous study reported that the median operative time for RRCS ranged from 240 to 310 min⁴⁶. With increasing experience, the operative time would be reduced in robotic surgery²⁹. It was reported that a surgical team requires approximately 30 cases to become comfortable and proficient with RRCS²⁸.

The following limitations of this meta-analysis should be considered. First, the included studies were not randomized controlled trials; some studies were prospective studies, and some were retrospective studies. Thus, the studies may have been biased, and the results should be interpreted with caution. Second, as a novel technique, the cost-effectiveness of RRCS should be considered. Of the included studies, only that of Berten et al.²³ reported the total cost, which was 11214€ for RRCS and 9858€ for ORCS; the combined data for this index were not available. However, a variety of studies have indicated that the cost of robotic colorectal surgery is higher than the cost of laparoscopic colorectal surgery^{8,47-49}. The high capital and running costs of robotic systems have precluded their widespread use in many countries⁵⁰. Third, the studies included patients with different basic characteristics and treatments, and these differences may have affected some of the results. Moreover, the surgeries in the included cases were carried out by different surgeons, and the different experiences and techniques of the surgeons may have affected some of the results³⁴. Fourth, only two studies reported the survival outcomes after long-term follow-up; more studies are needed to assess the survival outcome as well as the recurrence events. Fifth, the studies included in this meta-analysis were limited to those published in the English language because the authors of the present study were not literate in other languages. Thus, studies published in English may have more frequently supported our hypotheses, and studies reported in other languages may have more frequently refuted our hypotheses.

In conclusion, this meta-analysis suggests that RRCS is safe and effective. RRCS was associated with reduced EBL, less intraoperative transfusion requirements, a shorter time to flatus passage, a shorter time to resumption of a normal diet, and reduced LOS. There were no significant differences in complication rates, oncologic clearance,

and survival outcomes between the two groups. However, RRCS was associated with a longer operative time compared with ORCS. Future well-designed, larger, randomized controlled studies should be performed to assess the clinical and financial benefits and oncologic outcomes of RRCS to establish its role in the minimally invasive management of rectal cancer.

References

- 1. Desai, P. H., Lin, J. F. & Slomovitz, B. M. Milestones to optimal adoption of robotic technology in gynecology. *Obstet gynecol* 123, 13–20 (2014).
- Autorino, R., Zargar, H. & Kaouk, J. H., Robotic-assisted laparoscopic surgery: recent advances in urology. Fertil Steril 102, 939–949 (2014).
- 3. Maeso, S. *et al.* Efficacy of the Da Vinci surgical system in abdominal surgery compared with that of laparoscopy: a systematic review and meta-analysis. *Ann Surg* **252**, 254–262 (2010).
- Weber, P. A., Merola, S., Wasielewski, A. & Ballantyne, G. H. Telerobotic-assisted laparoscopic right and sigmoid colectomies for benign disease. Dis Colon Rectum 45, 1689–1694, 1695–1696 (2002).
- Baik, S. H. et al. Robotic versus laparoscopic low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. Ann Surg Oncol 16, 1480–1487 (2009).
- Collinson, F. J. et al. An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of roboticassisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int J Colorectal Dis 27, 233–241 (2012).
- Hara, M. et al. Robotic-assisted surgery for rectal adenocarcinoma: short-term and midterm outcomes from 200 consecutive cases at a single institution. Dis Colon Rectum 57, 570–577 (2014).
- Delaney, C. P., Lynch, A. C., Senagore, A. J. & Fazio, V. W. Comparison of robotically performed and traditional laparoscopic colorectal surgery. *Dis Colon Rectum* 46, 1633–1639 (2003).
- 9. Kariv, Y. & Delaney, C. P. Robotics in colorectal surgery. Minerva Chir 60, 401-416 (2005).
- Pigazzi, A., Ellenhorn, J. D., Ballantyne, G. H. & Paz, I. B. Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. Surg Endosc 20, 1521–1525 (2006).
- 11. Baek, S. J. *et al.* Robotic surgery for rectal cancer can overcome difficulties associated with pelvic anatomy. *Surg Endosc* 29, 1419–1424 (2015).
- 12. Baik, S. H. *et al.* Robotic tumor-specific mesorectal excision of rectal cancer: short-term outcome of a pilot randomized trial. *Surg Endosc* 22, 1601–1608 (2008).
- Park, J. S., Choi, G. S., Lim, K. H., Jang, Y. S. & Jun, S. H. Robotic-assisted versus laparoscopic surgery for low rectal cancer: casematched analysis of short-term outcomes. Ann Surg Oncol 17, 3195–3202 (2010).
- Liao, G. X. et al. Meta-analysis of outcomes compared between robotic and laparoscopic gastrectomy for gastric cancer. Asian Pac J Cancer Prev 14, 4871–4875 (2013).
- Yang, Y. et al. Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a metaanalysis. Ann Surg Oncol 19, 3727–3736 (2012).
- Memon, S., Heriot, A. G., Murphy, D. G., Bressel, M. & Lynch, A. C. Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. Ann Surg Oncol 19, 2095–2101 (2012).
- 17. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLOS MED* **6**, e1000097 (2009).
- Arezzo, A. *et al.* Laparoscopy for rectal cancer is oncologically adequate: a systematic review and meta-analysis of the literature. *Surg Endosc* 29, 334–348 (2015).
- Kim, J. C., Kwak, J. Y., Yoon, Y. S., Park, I. J. & Kim, C. W. A comparison of the technical and oncologic validity between robotassisted and conventional open abdominoperineal resection. Int J Colorectal Dis 29, 961–969 (2014).
- Kim, J. C. et al. Open versus robot-assisted sphincter-saving operations in rectal cancer patients: techniques and comparison of outcomes between groups of 100 matched patients. Int J Med Robot 8, 468–475 (2012).
- Biffi, R. et al. Operative blood loss and use of blood products after full robotic and conventional low anterior resection with total mesorectal excision for treatment of rectal cancer. J Robot Surg 5, 101–107 (2011).
- 22. Barnajian, M., Pettet, D. R., Kazi, E., Foppa, C. & Bergamaschi, R. Quality of total mesorectal excision and depth of circumferential resection margin in rectal cancer: A matched comparison of the first 20 robotic cases. *Colorectal Dis* **16**, 603–609 (2014).
- Bertani, E. et al. Assessing appropriateness for elective colorectal cancer surgery: clinical, oncological, and quality-of-life short-term outcomes employing different treatment approaches. Int J Colorectal Dis 26, 1317–1327 (2011).
- DeSouza, A. L. et al. A comparison of open and robotic total mesorectal excision for rectal adenocarcinoma. Dis Colon Rectum 54, 275–282 (2011).
- Ghezzi, T. L. et al. Robotic versus open total mesorectal excision for rectal cancer: Comparative study of short and long-term outcomes. Eur J Surg Oncol 40, 1072–1079 (2014).
- 26. Kang, J. et al. The impact of robotic surgery for mid and low rectal cancer: a case-matched analysis of a 3-arm comparison-open, laparoscopic, and robotic surgery. Ann Surg 257, 95-101 (2013).
- 27. Kim, J. C. *et al.* Completely abdominal intersphincteric resection for lower rectal cancer: feasibility and comparison of robot-assisted and open surgery. *Surg Endosc* 28, 2734–2744 (2014).
- Park, J. S., Choi, G. S., Lim, K. H., Jang, Y. S. & Jun, S. H. S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer. Surg Endosc 25, 240–248 (2011).
- 29. Liao, G. et al. Robotic versus open gastrectomy for gastric cancer: a meta-analysis. Plos one 8, e81946 (2013).
- Zong, L., Seto, Y., Aikou, S. & Takahashi, T. Efficacy Evaluation of Subtotal and Total Gastrectomies in Robotic Surgery for Gastric Cancer Compared with that in Open and Laparoscopic Resections: A Meta-Analysis. *PLos one* 9, e103312 (2014).
- Zhang, J., Wu, W. M., You, L. & Zhao, Y. P. Robotic versus open pancreatectomy: a systematic review and meta-analysis. Ann Surg Oncol 20, 1774–1780 (2013).
- 32. Wu, Z. et al. Robotic versus open partial nephrectomy: a systematic review and meta-analysis. PLos One 9, e94878 (2014).
- 33. Tang, K. *et al.* Robotic vs. open radical cystectomy in bladder cancer: A systematic review and meta-analysis. *Eur J Surg Oncol* **40**, 1399–1411 (2014).
- 34. Liao, G. *et al.* Robotic-assisted versus laparoscopic colorectal surgery: a meta-analysis of four randomized controlled trials. *World J Surg Oncol* **12**, 122 (2014).
- Amato, A. & Pescatori, M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev D5033 (2006).
- Morner, M. E., Gunnarsson, U., Jestin, P. & Svanfeldt, M. The importance of blood loss during colon cancer surgery for long-term survival: an epidemiological study based on a population based register. *Ann Surg* 255, 1126–1128 (2012).
- Basilico, V. et al. Anastomotic leakage following colorectal resection for cancer: how to define, manage and treat it. Minerva Chir 69, 245–252 (2014).
- Kim, C. W., Kim, C. H. & Baik, S. H. Outcomes of robotic-assisted colorectal surgery compared with laparoscopic and open surgery: a systematic review. J Gastrointest Surg 18, 816–830 (2014).

- Hellan, M., Anderson, C., Ellenhorn, J. D., Paz, B. & Pigazzi, A. Short-term outcomes after robotic-assisted total mesorectal excision for rectal cancer. Ann Surg Oncol 14, 3168–3173 (2007).
- Guillou, P. J. et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365, 1718–1726 (2005).
- 41. Bosch, S. L. & Nagtegaal, I. D. What Is "Good Quality" in Rectal Cancer Surgery? The Pathologist's Perspective. *Recent Results Cancer Res* 203, 41–46 (2014).
- 42. La Torre, M. *et al.* The importance of lymph node retrieval and lymph node ratio following preoperative chemoradiation of rectal cancer. *Colorectal Dis* 15, e382–e388 (2013).
- 43. Dhadda, A. S., Bessell, E. M., Scholefield, J., Dickinson, P. & Zaitoun, A. M. Mandard tumour regression grade, perineural invasion, circumferential resection margin and post-chemoradiation nodal status strongly predict outcome in locally advanced rectal cancer treated with preoperative chemoradiotherapy. *Clin Oncol (R Coll Radiol)* 26, 197–202 (2014).
- 44. Madbouly, K. M., Abbas, K. S. & Hussein, A. M. Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study. *Am J Surg* **207**, 824–831 (2014).
- Mezhir, J. J. et al. Whole-mount pathologic analysis of rectal cancer following neoadjuvant therapy: implications of margin status on long-term oncologic outcome. Ann Surg 256, 274–279 (2012).
- Pigazzi, A. *et al.* Multicentric study on robotic tumor-specific mesorectal excision for the treatment of rectal cancer. Ann Surg Oncol 17, 1614–1620 (2010).
- Akmal, Y., Baek, J. H., McKenzie, S., Garcia-Aguilar, J. & Pigazzi, A. Robot-assisted total mesorectal excision: is there a learning curve ? Surg Endosc 26, 2471–2476 (2012).
- 48. DeSouza, A. L. et al. Robotic assistance in right hemicolectomy: is there a role? Dis Colon Rectum 53, 1000-1006 (2010).
- Halabi, W. J. et al. Robotic-assisted colorectal surgery in the United States: a nationwide analysis of trends and outcomes. World J Surg 37, 2782–2790 (2013).
- 50. Aly, E. H. Robotic colorectal surgery: summary of the current evidence. Int J Colorectal Dis 29, 1-8 (2014).

Author Contributions

Z.Z., G.X.L., Y.-B.L. and X.L. conducted the literature search, identified the studies for exclusion and inclusion, extracted data from the retrieved studies, performed the meta-analysis, and drafted the manuscript. G.L.,Y.-B.L., X.L. and H.D. provided comments on the experiment design and the manuscript and read and approved the final manuscript. All authors reviewed the paper and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liao, G. *et al.* Robotic-assisted surgery versus open surgery in the treatment of rectal cancer: the current evidence. *Sci. Rep.* **6**, 26981; doi: 10.1038/srep26981 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/